CD4 and myeloid sarcoma: Interestingly, Muraro et al. showed that the proportion of effector memory CD4+ cells (CD4+CD45RA−CD45RO+CD27−) increased significantly at 6 months after successful aHSCT in MS, which argues against a pathogenic role for the observed induction of CD4 and CD8 effector memory cells [78].